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TIIVISTELMÄ 
Tutkimuksen tausta ja tavoitteet: Eturauhassyöpä on yleisin miehillä diagnosoitu syöpä. 
Vaikka syöpä on tavallisesti hitaasti etenevä ja diagnosoidut potilaat menehtyvät tyypillisesti 
muun sairauden seurauksena, on eturauhassyöpä silti kolmanneksi yleisin syöpäkuolemien 
aiheuttaja miehillä. Nykyiset diagnostiset menetelmät eivät luotettavasti erota aggressiivisia 
syöpätapauksia hitaasti etenevistä. Tarvitaankin uusia taudinkulun paremmin määritteleviä 
menetelmiä, jotta hoitomuodot voidaan valita histopatologisten löydösten ja syövän 
molekulaarisien ominaisuuksien perusteella parhaan hoitotuloksen takaamiseksi. Tämän 
saavuttamiseksi eturauhassyövän molekulaariset mekanismit on tunnettava paremmin. 
Kliinisten näytteiden geeniekspressioita tutkimalla on havaittu, että OXGR1-yliekspressiolla 
saattaisi olla merkitystä joidenkin eturauhassyöpätyyppien synnyssä. Tämän tutkimuksen 
tarkoituksena oli selvittää OXGR1-yliekspression vaikutuksia kahden eturauhassyöpäsolulinjan 
kasvunopeuteen vaihtelevissa substraattipitoisuuksissa. 
Tutkimusmenetelmät: Tutkimuksessa käytettiin aiemmin luotuja stabiilisti OXGR1 
yliekspressoivia PC-3 ja LNCaP -eturauhassyöpäsolulinjoja. Solujen ekspressioprofiilit 
määritettiin RT-qPCR-, western blot- ja immunofluoresenssivärjäysmenetelmillä. 
Kasvunopeuskokeet suoritettiin kuoppalevyillä käyttäen kasvatusliuoksessa eri pitoisuuksia 
glukoosia, glutamiinia ja alfaketoglutaraattia, joka on OXGR1:n ligandi. Solujen kasvu 
kuvattiin ja kasvunopeus määritettiin mittaamalla solujen pinta-ala ohjelmallisesti. 
Tulokset: Kaikkien transfektoitujen solulinjojen OXGR1-mRNA -tasot olivat korkeita 
verrattuna kontrolleihin. Western blot -kokeet osoittivat transfektoitujen LNCaP-linjojen 
proteiiniekspression selvästi kasvaneen. Näiden linjojen kasvu myös nopeutui kokeessa, jossa 
alfaketoglutaraatin pitoisuutta lisättiin. PC-3-linjoilla proteiiniekspressio oli samankaltainen 
transfektoiduilla ja kontrolleilla. Kasvunopeudessakaan ei havaittu muutoksia. Western blot-
kokeissa OXGR1 vasta-aineen osoittama proteiini oli yli 10 kilodaltonia odotettua suurempi. 
Johtopäätökset: Tulokset antavat viitteitä, että OXGR1:n yliekspressiolla voisi olla merkitystä 
eturauhassyövän synnyssä ja osoittavat, että stabiilisti OXGR1:tä yliekspressoivia LNCaP -
solulinjoja voidaan käyttää jatkotutkimuksissa. OXGR1 vasta-aineen oikea sitoutuminen tulee 
validoida ja selvittää syy havaittuun eroon proteiinin koossa. Jatkotutkimuksissa tulisi selvittää 
laajemmin OXGR1:n vuorovaikutuksia syövän synnyssä. Tämä olisi mahdollista toteuttaa 
OXGR1-yliekspressiolla eturauhassyövän hiirimallissa. 
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ABSTRACT 
Background and aims: Prostate cancer is the most common cancer diagnosed in men. While 
it often has indolent course, and diagnosed men more commonly perish to comorbidities, it 
remains the third-leading cause of cancer death in men. Current diagnostic tools fail to reliably 
distinguish aggressive cancer cases from indolent ones and new tools with better prognostic 
value are needed to address this. Preferably, a well-informed treatment choice based on 
histopathological findings and molecular characteristics of cancer could be made to achieve 
best possible treatment outcome. To succeed in this, molecular mechanisms of prostate cancer 
must be better understood. Based on gene expression profiles from clinical samples, 
overexpression of OXGR1 could be a cancer promoting factor in certain prostate cancer 
subtypes. The aim of this study was to characterize effects of OXGR1 overexpression to growth 
rate of two prostate cancer cell lines in varying key substrate concentrations. 
Methods: OXGR1 overexpressing PC-3 and LNCaP prostate cancer cells lines were created 
previously by stable transfections with pcDNA3.1 vectors having OXGR1 under constitutive 
promoter. Expression profiles of cells were characterized with RT-qPCR, western blot and 
immunofluorescence staining. Growth rate experiments were performed in well plates using 
different concentrations of glucose, glutamine and alpha-ketoglutarate, which is a ligand for 
OXGR1, in growth medium.  Cells were imaged at intervals and growth rate was defined by 
measuring surface area programmatically.  
Results: All transfected cell lines had high OXGR1 mRNA levels compared to controls. In 
LNCaP cell lines western blot results showed clear increase in protein expression of transfected 
lines. In transfected LNCaP cell lines an increase in growth rate was seen as the alpha-
ketoglutarate concentration was increased. In PC-3 cell lines the protein levels were similarly 
low regardless of transfection status. OXGR1 overexpression had no effect on growth rate of 
PC-3 cells in any of the growth conditions. OXGR1 antibody used in western blot experiments 
produced a clear band over 10 kilodaltons larger than the predicted band size. 
Conclusions: These results show promise that OXGR1 overexpression could have significance 
in prostate cancer promotion and that stable OXGR1 expressing LNCaP cell lines can be used 
to study this further. However, proper binding of the OXGR1 antibody must be validated and 
the cause of shift in band size elucidated. Studies that take more molecular interactions into 
account are probably needed to clarify the role of OXGR1 overexpression in prostate cancer. 
This could possibly be done by performing OXGR1 overexpression studies in prostate cancer 
mouse model. 
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1  INTRODUCTION 
Prostate cancer is the most common cancer in males in Finland and the second most common 
cancer in males worldwide (Ferlay et al. 2015; Finnish Cancer Registry 2017). Although 
prostate cancer often has indolent course, and is typically a disease of elderly men, it remains 
the second leading cause of cancer-related death in Finland and a cause for distress for the 
families affected (Finnish Cancer Registry 2017). Most important risk factors for prostate 
cancer are age, African-American ethnicity, and family history. One third of the familiar 
increase in risk of being diagnosed with prostate cancer is accounted for by known prostate 
cancer associated genetic aberrations (Olama et al. 2014). Several protective factors, such as 
physical activity, vitamin intake, diet, and various drugs have been studied, but nothing with 
substantial benefits have been found. 
Almost all prostate cancers are adenocarcinomas that develop when glandular prostate 
cells become malignant. These cells grow into localized tumors that can either be contained in 
the prostate, or spread to surrounding tissues such as seminal vesicles, bladder, or the rectum 
(Prostate cancer: Current Care Guidelines, 2014). Prostate cancer most commonly metastasizes 
to the bones and lymph nodes. Localized cancer can be curatively treated by either radical 
prostatectomy or radiotherapy, though a fraction of cases develops into recurrent metastatic 
disease. Metastatic disease is treated with androgen deprivation therapy (ADT), which halts the 
disease progression until castration resistant prostate cancer (CRPC) develops. CRPC is always 
fatal, but can be treated with new drugs that interfere with androgen pathway and slow disease 
progression. Heterogenous nature of prostate cancer has made characterization of mechanisms 
of disease initiation and progression difficult. Recent advances in high-throughput genetic 
technologies together with mechanistic studies are providing important information, but 
translation of the data to advances in treatment and diagnostics is still in infancy. 
Prostate cancer diagnosis is made based on an ultrasound biopsy, which is taken if 
digital rectal examination (DRE) and prostate-specific antigen (PSA) levels in blood give 
reason to suspect cancer (Mohler et al. 2016; Prostate cancer: Current Care Guidelines, 2014). 
PSA is not specific to prostate cancer and is increased also in benign conditions of prostate. 
Indolent cancer cases cannot reliably be discriminated from aggressive ones based on biopsy 
and PSA levels alone. These are the main reasons that have led to overdiagnosis and 
overtreatment of prostate cancer, which, as widespread consensus acknowledges, are problems 
that should be addressed by more accurate diagnostic and prognostic tools.  
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In the literature review section of this thesis, an overview of current knowledge on 
epidemiology and risk factors, and of state of the art practices in diagnosing and treating 
prostate cancer is given. The main focus is on genetic aberrations underlying prostate cancer, 
and on emerging biomarkers that show promise in better characterization of the disease in its 
early stages, making an informed choice of the best treatment options possible. 
In the study section, the possible role of OXGR1 in prostate cancer is assessed. High-
throughput RNA sequencing data of clinical prostate cancer samples show significant 
overexpression of OXGR1 in a small subset of samples. As there is no published data suggesting 
OXGR1 to be a cancer promoting factor, the main aim of the study was to investigate whether, 
and by which mechanisms, OXGR1 expression and the protein coded by it, 2-Oxoglutarate 
receptor 1 (OXGR1), could confer growth advantage to prostate cancer cells.  
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2  REVIEW OF THE LITERATURE 
2.1  Prostate cancer 
2.1.1  Epidemiology of prostate cancer 
Prostate cancer is the most common cancer in males in Finland and the second most common 
cancer in males worldwide (Ferlay et al. 2015; Finnish Cancer Registry 2017). Number of new 
diagnosed cases per year (incidence) in Finland in 2015 was 4855 and number of deaths per 
year in 2015 was 921, which translates to 14% of all cancer deaths in men (Finnish Cancer 
Registry 2017).  
As seen in Figure 1, the incidence of prostate cancer began to increase dramatically 
in the developed countries during the 1990’s, while mortality has begun to decrease slightly 
during the same period. The increase in the incidence is mainly explained by the development 
and wide use of PSA testing which has led to diagnosis of docile prostate cancer cases that 
would have otherwise remained undiagnosed (Schroder et al. 2014). At least part of the 
simultaneous decrease in mortality rate may also be attributed to the advent of PSA testing 
(Kvale et al. 2007; Schroder et al. 2014). Other mortality decreasing factors include the 
adoption of early curative treatment of localized prostate cancer with radical prostatectomy or 
radiotherapy, and improved treatment of more advanced disease (Kvale et al. 2007). 
Figure 1: Incidence and mortality of prostate cancer in selected countries. a) Age-standardized incidence 
per 100 000. * Regional data. b) Estimated (WHO) age-standardized mortality per 100 000. WHO’s 
world standard population was used in age standardization. Figure from Ferlay J et al, 2013. 
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2.1.2  Risk factors  
While the pathogenesis of prostate 
cancer is not completely 
understood, several risk factors that 
increase individuals’ likelihood to 
get cancer have been established. 
As seen in Figure 2, the risk of 
being diagnosed with prostate 
cancer rises dramatically as the 
individual ages (Finnish Cancer 
Registry 2017). Aging increases 
prostate cancer risk in different 
ways. As with almost all cancers, 
aging allows for more time for accumulation of DNA damage in the prostate both due to internal 
and external carcinogens (Serrano and Blasco 2007). Inflammation processes have been linked 
to initiation and progression of prostate cancer, and immune system function is altered with 
aging (Sfanos and De Marzo 2012). This is characterized for example by decreased T cell 
differentiation and increased amount of pro-inflammatory cytokine secretion (Fagnoni et al. 
2000; Kim et al. 2011). These processes have been linked to prostate tumorigenesis in prostate 
cancer cell line studies (De Angulo et al. 2015). 
 Prostate cancer incidence rates vary greatly depending of race. Age-adjusted 
incidence rates per 100 000 people in the United States during 2010-2014 were 189, 113, and 
63, for African-American, Caucasian, and Asian men, respectively (National Cancer Institute 
2017). Black men are also found to have from 44% to 75% higher risk at the time of diagnosis, 
compared to general population, to develop metastatic disease (Tsodikov et al. 2017). There is 
also geographic variation in prostate cancer incidence. For example, Asian men living in United 
States have higher incidence than in their country of origin (Goggins and Wong 2009). The 
reasons for this are unclear, though differences in screening and lifestyle changes are likely to 
effect (Goggins and Wong 2009; Hemminki et al. 2013). 
Men with first-degree relative diagnosed with prostate cancer have 2.5 times higher 
risk to develop the disease (Kicinski et al. 2011). The risk is higher in men under 65 (2.9) and 
even higher with men whose affected relative is a brother (3.14) (Kicinski et al. 2011). 33% of 
the familiar risk is accounted for in the European ancestry population with most susceptibility 
Figure 2: Age-specific incidence of prostate cancer in Finland 
in 2011-2015. Figure modified from Finnish Cancer Registry 
(https://tilastot.syoparekisteri.fi) (9.10.2017). 
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loci conferring only a small increase in risk (Olama et al. 2014). Men under 65 with rare BRC1 
and BRCA2 mutations have in estimate 3.4 and 8.6 times higher risk of prostate cancer and are 
more likely to develop aggressive disease (Kote-Jarai et al. 2011; Leongamornlernt et al. 2012). 
HOXB13 G84E mutation also confers 3.4 times higher risk of developing prostate cancer, but 
other mutations conferring similar risk increases haven’t been detected (Cuzick et al. 2014; 
Karlsson et al. 2014).  
There is some evidence that ionizing radiation used in diagnostic procedures and UV 
radiation from sun exposure could increase prostate cancer risk, but the studies are limited 
(Myles et al. 2008; Nair-Shalliker et al. 2012). The role of urinary tract infections in 
development of prostate cancer has been studied, and Trichomonas vaginalis infection and 
chronic intra-prostatic inflammation might be involved in the development of prostate cancer 
(De Marzo et al. 2007; Sutcliffe et al. 2012). 
 A meta-analysis of 24 prospective cohort studies found that cigarette smoking 
modestly increases prostate cancer mortality, but not incidence (Islami et al. 2014). This is 
substantiated by a study examining biopsy-negative men with protocol-dictated PSA-
independent rebiopsies that found smoking to be associated with higher grade disease, but not 
with overall prostate cancer diagnosis (Ho et al. 2014). 
 An overview of studies suggests that higher BMI is associated with an increased risk 
of advanced prostate cancer but a decreased risk in localized disease (Discacciati and Wolk 
2014). Many dietary factors have been studied, but there is no solid evidence for association 
with prostate cancer (Discacciati and Wolk 2014). A large meta-analysis found that physical 
exercise slightly reduces the risk for prostate cancer (Liu et al. 2011).  
Many protective factors, such as the higher intake of antioxidant vitamin E and 
selenium, cofactor of several antioxidant enzymes, have been studied extensively, but they were 
not found to reduce the risk of prostate cancer (Klein et al. 2011). There is limited evidence 
from cohort studies and randomized trials that regular aspirin intake could reduce prostate 
cancer incidence and mortality (Bosetti et al. 2011; Rothwell et al. 2011). However, results are 
heterogenous and the dose and duration-risk relationships are not clear.  
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2.1.3  Diagnosis 
If DRE and / or blood test for PSA give reason to suspect 
prostate cancer, a transrectal ultrasound systematic 
prostate biopsy of 10 to 12 tissue samples from different 
parts of the prostate is taken (Mohler et al. 2016; Prostate 
cancer: Current Care Guidelines, 2014).  This biopsy is 
the main basis for diagnosis. A Gleason grade from 1 to 5 
is issued based on gland differention in the tissue samples, 
with 1 being well differentiated (Figure 3). A primary 
Gleason grade is issued based on what pattern is most 
commonly seen and a secondary Gleason grade is issued 
based on the second most commonly seen pattern. A 
recently introduced and adopted system, attempting to 
better discriminate between indolent and aggressive 
cancer types, grades prostate cancer to 5 groups based on 
Gleason scores (table 1) (Epstein et al. 2016). If metastasis 
of cancer is suspected on grounds of symptoms, high grading, high PSA or other risk factors, 
bone scans and other imaging tests are performed (Prostate cancer: Current Care Guidelines, 
2014).  
Table 1: Grading of prostate cancer. Table modified from Epstein et al. 2016. 
 
 
 
 
 
 
 
 
 
 
Risk grade Gleason scores Histological description 
Grade 1 cancer Gleason score of ≤ 6 
Only individual, discrete, well-formed 
glands 
Grade 2 cancer Gleason score of 3 + 4 
Predominantly well-formed glands 
with lesser component of poorly 
formed, fused, or cribiform glands 
Grade 3 cancer Gleason score of 4 + 3 
Predominantly poorly formed, fused, 
or cribiform glands with lesser 
component of well-formed glands 
Grade 4 cancer 
Gleason scores of 4 + 4, 
3 + 5, and 5 + 3 
Only poorly formed, fused, or 
cribiform glands or well-formed 
glands plus area lacking glands 
Grade 5 cancer 
Gleason scores of 4 + 5, 
5 + 4, and 5 + 5 
Lacks gland formation (or with 
necrosis) with or without poorly 
formed, fused, or cribiform glands 
Figure 3: A Gleason grading chart. 
Image from Epstein et al. 2016. 
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21 to 28 percent of cancer cases are missed when only a systematic biopsy is used for 
diagnosis (Bjurlin et al. 2013). Serum PSA variant levels, along with emerging biomarkers such 
as PCA3 and DNA methylation status of prostate biopsy tissue, can be utilized in search for 
false negatives (Gupta et al. 2010; Partin et al. 2014; Wei et al. 2014). Another recent 
development is the use of multiparametric magnetic resonance imaging (MRI) in performing 
targeted biopsies, commonly in addition to systematic biopsies (Weinreb et al. 2016; Filson et 
al. 2016). It holds promise of more specific and sensitive diagnosis, but further validation and 
setting of guidelines is still needed (Rosenkrantz et al. 2016). 
2.1.4  Treatment 
Localized prostate cancer: When deciding treatment strategy for localized prostate cancer, 
accurate prognosis, patient age and life expectancy, effects of chosen treatments side effects on 
the quality of life, and patient’s comorbidities all play an important role (Litwin and Tan 2017). 
Most important prognostic factors are clinical staging, which takes into account the spreading 
of the disease, cancer grade (table 1), and serum PSA levels (Prostate cancer: Current Care 
Guidelines, 2014). Accurate prognosis, especially for cancer cases with Gleason scores 6 and 
7, has proven difficult with the traditional methods (Irshad et al. 2013). New gene assays 
attempting to predict cancer progression from biopsy tissue samples have been presented with 
some success (Klein et al. 2014; Knudsen et al. 2016; Sommariva et al. 2016). A 14-year follow 
up study to patients with nonmetastatic prostate cancer at diagnosis found other-cause mortality 
rates ranging from 24% to 57%, depending from the number of co-morbidities, whereas the 
prostate cancer-specific mortality ranged from 3% to 18%, depending of risk rating based on 
clinical stage, Gleason score, and PSA level (Daskivich et al. 2013). Decision aids for prostate 
cancer patients have been introduced to facilitate shared decision making, which could better 
take into account effects to quality of life caused by the side effects of chosen treatment. A 
meta-analysis of decision aid trials states that only limited or no benefits have been gained by 
their use, so further development and study is needed (Violette et al. 2015). 
Three primary treatment options are available for localized prostate cancer: Expectant 
management, surgery and radiation. Expectant management can be divided to watchful waiting, 
where disease progress is monitored by patient’s symptoms only, and active surveillance, which 
consists of serial PSA testing, physical examinations and rebiopsies (Filson et al. 2015). This 
approach is taken to limit the adverse effects of over treatment and is supported by studies with 
selected low-risk patients with Gleason scores 7 or less undergoing active surveillance finding 
the risk of metastasis and prostate cancer mortality to range from 0% to 6.1% (Godtman et al. 
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2016; Hamdy et al. 2016; Klotz et al. 2015; Tosoian et al. 2015; Welty et al. 2015). One of 
these studies compared the 10 year outcomes of active surveillance, surgery and radiation 
therapy, finding only minor, non-significant differences in prostate cancer-specific mortality 
and better quality of life in men with active surveillance (Hamdy et al. 2016; Donovan et al. 
2016).  
 Surgery or radiation therapy are chosen as treatment when the disease is deemed more 
likely to advance, either at primary diagnosis or after worsened prognosis during active 
surveillance (Litwin and Tan 2017). Commonly used indications are PSA value of over 10 ng 
/ ml and nodules palpable on DRE (Litwin and Tan 2017). Surgery is a radical prostatectomy, 
where whole prostate is removed with its capsule. Also, regional lymph nodes can be removed 
if biopsies (Gleason score ≥ 8) and PSA value (>10 µg / l) suggest more aggressive disease 
(Prostate cancer: Current Care Guidelines, 2014). The use of robot-assisted laparoscopic 
prostatectomy has quickly become the standard procedure, and it has been shown to reduce 
adverse effects in comparison to open radical prostatectomy, such as loss of urinary and sexual 
function (Ficarra et al. 2012a, Ficarra et al. 2012b). The curative power of these surgeries is 
considered similar, as no significant difference in proportion of positive surgical margins has 
been found (Yaxley et al. 2016). Adjuvant radiotherapy is considered, and has been found 
effective in long term trials, after surgery in high risk patients, such as those with positive 
surgical margins (Bolla et al. 2012; Wiegel et al. 2014). 
 Radiation therapy is commonly combined with ADT (Mohler et al. 2016). 6 months 
of ADT in intermediate risk patients and ≥ 24 months of ADT in high risk patients, both started 
before radiation therapy, have been found effective in randomized clinical trials (Bolla et al. 
2016; Zapatero et al. 2015). Radiation therapy is carried out as external beam radiotherapy 
(EBRT) or brachytherapy in case of intermediate risk or a combination of both in high risk 
patients (Mohler et al. 2016). Recent advances in EBRT include better radiation beam targeting, 
enabling higher radiation dose delivery to prostate, reduction of side effects caused by radiation 
to surrounding organs, and improved cancer control (Dearnaley et al. 2014; Viani et al. 2016). 
 Previous studies summarized in meta-analysis have indicated lower mortality with 
surgery than radiotherapy, however, first randomized comparison of these treatment options 
found no difference in prostate cancer mortality (0.9% and 0.7 for surgery and radiation, 
respectively) or clinical progression (8.3% and 8.4% for surgery and radiation, respectively) 
during 10-year follow-up (Hamdy et al. 2016; Wallis et al. 2016). After surgery, the prostate 
can be fully analyzed to accurately grade the disease. Also, PSA should be undetectable when 
no normal or cancerous prostate cells exist, enhancing monitoring for recurrence (Paller and 
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Antonarakis 2013). This is not the case with radiation therapy, after which the PSA values 
typically decrease, but fluctuation is also observed (Djavan et al. 2003). Another important 
consideration when choosing proper treatment is the impact of side effects to the quality of 
patients’ life. Most important side effects are sexual dysfunction and urinary incontinence for 
radical prostatectomy, and sexual dysfunction and bowel problems for radiation therapy, but 
these are affected by baseline functions in patients (Chen et al. 2009). 
Metastatic Prostate Cancer: Prostate cancer commonly metastasizes to bone (80 to 
90 percent of metastatic cases) and lymph nodes (40 to 50 percent of metastatic cases) (Mohler 
et al. 2016). The standard therapy to metastatic disease is ADT (Prostate cancer: Current Care 
Guidelines, 2014). ADT is performed by orchiectomy, luteinizing hormone-releasing hormone 
(LHRH) agonists, or antagonists which all result in considerably lowered androgen levels 
(Gillessen et al. 2017). This treatment strategy halts the disease progression for ~ 0.5 to 2 years, 
after which a castration resistant disease is developed (James et al. 2015). Due to serious side 
effects of ADT, such as decreased bone mineral density, metabolic changes, sexual dysfunction, 
cardiac morbidity and cognitive dysfunction, the effect of intermittent ADT has been studied 
(Nead et al. 2017; Nguyen et al. 2015). A recent meta-analysis found intermittent ADT as 
effective as standard ADT, with minor improvements in physical and sexual function (Magnan 
et al. 2015). A well tolerated cytostatic, docetaxel, can be combined with ADT, with two 
randomized trials reporting considerable delays in cancer progression and increases in cancer 
survival times (James et al. 2016; Sweeney et al. 2015). 
 ADT is advised to be continued when cancer progresses to castration resistant state, 
although there are no recent studies confirming its usefulness with the new treatment options 
(Cornford et al. 2017; Hussain et al. 1994). Two new drugs targeting androgen pathways have 
been developed and recently adopted for treatment of metastatic castration resistant prostate 
cancer (mCRPC) (Cornford et al. 2017). Abiraterone acetate inhibits androgen biosynthesis and 
enzalutamide interferes with androgen receptor (AR) signaling. Both have been shown to slow 
disease progression and improve survival and quality of life in randomized clinical trials (de 
Bono et al. 2011; Scher et al. 2012). Docetaxel has also been found beneficial for survival times 
and can be used as treatment for mCRPC if not utilized before (Armstrong et al. 2010; Cornford 
et al. 2017). Another emerging treatment option for asymptomatic or minimally symptomatic 
mCRPC is Sipuleucel-T, a cancer vaccine found to increase median survival time for 4 months 
(Kantoff et al. 2010). Common painful bone metastases can be palliatively treated with 
radiation therapy, which can considerably improve quality of live (Hartsell et al. 2005). Bone 
targeting agents such as denosumab and zoledronic acid can be used to reduce skeletal-related 
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events (SRE) associated with mCRPC, such as fractures and spinal cord compression (Saad et 
al. 2002; Smith et al. 2012). 223Radium, an α-emitter particle that selectively binds to bony 
metastases is the first bone-targeted therapy shown to increase prostate cancer survival. In 
randomized trial, it increased median overall survival by 3.6 months and delayed first SRE by 
5.8 months, in comparison to placebo (Parker et al. 2013). 
 Quality of life considerations: From 2006 to 2012, the five-year survival rates for 
local and regional disease were close to 100% and for distant metastatic disease 30% (Siegel et 
al. 2017). In Finland, the 5-year survival for all diagnosed prostate cancer cases in 2013-2015 
was 94% (Finnish Cancer Registry 2017). As prostate cancer can be better controlled with new 
treatment options and strategies, treatments and interventions supporting active life are 
becoming increasingly important. Couples therapy and treating of erectile dysfunction caused 
by ADT and radiotherapy with sildenafil have been found to improve quality of life (Couper et 
al. 2015; Watkins Bruner et al. 2011). Pelvic floor muscle exercise has been shown to improve 
urinary continence after localized prostate cancer treatment (Zhang et al. 2015). Diet and 
exercise interventions especially for patients undergoing ADT for metastatic disease have 
proven to be effective in improving quality of life (Bourke et al. 2014; Bourke et al. 2016).
  
2.1.5  Genetics of prostate cancer 
In over 80% of men diagnosed with prostate cancer, multiple tumor foci are detected in the 
prostate (Svensson et al. 2011). Recent studies utilizing whole genome sequencing (WGS) and 
exome sequencing suggest that these foci are of independent origin (Cooper et al. 2015; 
Lindberg et al. 2013). This find is supported by a study examining the differences in the most 
common genetic rearrangements between different tumor foci (Svensson et al. 2011). 
Interestingly, analysis of WGS data from tumors and their metastatic sites reveals that 
metastases commonly originate from single foci (Gundem et al. 2015). After metastasis, re-
seeding from metastases to primary foci and other metastases commonly takes place, reducing 
tumor heterogeneity (Gundem et al. 2015; Hong et al. 2015). This is especially important during 
chemotherapy, since there is evidence of cross-metastatic seeding of treatment resistant cells 
(Hong et al. 2015). 
 Prostate cancer is characterized by gene fusions and copy-number aberrations (CNA) 
with only some point mutations of general importance. This makes pinpointing the genes 
primarily responsible for oncogenesis difficult, since for example loss of heterozygosity (LOH) 
and chromosomal gains can cause differential expression of multitude of genes. Some progress 
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has been made by pan-cancer analyses of CNAs, suggesting for example that deregulation of 
DNA mismatch repair could predispose to prostate cancer (Zack et al. 2013). Some of the most 
important known chromosomal rearrangements and mutations, along with epigenetic features, 
for prostate cancer development and progression are summarized in the following section. 
 ETS fusion genes: ETS transcription factor gene fusions are detected in about half of 
prostate cancer cases. The most common of these is the linkage of TMPRSS2 androgen-
responsive promoter and the transcription factor gene ERG (Tomlins et al. 2007). At least one 
mechanism of the fusion is thought to be prolonged exposure to androgens, increased AR 
activity and inhibition of the double-strand break preventing protein PIWIL1 (Bastus et al. 
2010). AR transcription complex brings ERG and TMPRSS2 loci in contact and DNA double-
strand break repair mechanisms can lead to fusion of the two genes (Mani et al. 2009; Wu et al. 
2011). ETS fusion positive prostate cancer cases are often associated with additional inter-
dependent chromosomal rearrangements appearing early in cancer progression (Baca et al. 
2013). The precise mechanism by which these rearrangements occur is not fully known, but 
there is evidence of AR signaling playing a key role (Weischenfeldt et al. 2013). TMPRSS2-
ERG gene fusions have been studied extensively, but taken alone their explanatory power to 
prostate cancer progression is inconsistent (Tomlins et al. 2009). However, TMPRSS2-ERG 
fusions are associated with younger age at diagnosis and lower PSA values (Schaefer et al. 
2013). When observed with other defects such as increased AR activity or PTEN loss, 
TMPRSS2-ERG fusions are shown to lead to invasive adenocarcinoma (Carver et al. 2009). 
Androgen signaling: AR is a hormone receptor that mediates its effects primarily as 
a DNA binding transcription factor in response to androgen stimuli (Heinlein and Chang 2002). 
It has also been shown to have non-genomic actions for example by directly inducing the 
MAPK signal cascade in the cytoplasm (Heinlein and Chang 2002). AR signaling is crucial to 
development of both normal prostate and its cancer and androgen ablation therapy is standard 
treatment for advanced metastatic prostate cancer (Shen and Abate-Shen 2010). AR signaling 
can be aberrantly increased and become ligand-independent, thus promoting the development 
of androgen-independent prostate cancer, due to AR gene amplification, point mutations and 
alternative splice variants (Grasso et al. 2012; Visakorpi et al. 1995). These are detected already 
in localized tumors, but much more frequently in castration resistant cases (Grasso et al. 2012). 
Mutations and CNAs of genes regulating AR signaling have been detected in both localized 
and metastasized prostate cancer cases. FOXA1 codes for an AR cofactor and its recurrently 
detected mutations are shown to increase tumor growth (Grasso et al. 2012). Another such gene 
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is NCOA2, whose overexpression is shown to increase recurrence rates after radical 
prostatectomy (Taylor et al. 2010). 
LOH in 5q and 6q regions: Losses in genetic material in 5q and 6q chromosomal 
arms are mainly seen in ETS fusion negative cases of prostate cancer (Mitchell and Neal 2015). 
The most notable prostate cancer linked gene in 5q arm is CDH1. In addition to LOH, CDH1 
point mutations and rearrangements have also been reported in prostate cancer (Grasso et al. 
2012). Loss of CDH1 is associated in increase in both CNAs and intra-chromosomal re-
arrangements in prostate cancer (Baca et al. 2013). CDH1 codes for cadherin protein with 
important role in cell adhesion. Its downregulation in prostate cancer is associated with loss of 
differentiation, advanced clinical stage, and poor survival (Ikonen et al. 2011).  Losses of 
genetic material in 6q12-6q22 region are common in prostate cancer and associate with 
aggressive disease (Kluth et al. 2013; Williams et al. 2014). MAP3K7 is thought to be the key 
tumor suppressor gene in the region, since it governs transcription regulation and apoptosis 
pathways (Mihaly et al. 2014). 
 PTEN inactivation: PTEN is a tumor suppressor gene that downregulates PI3K-
dependant signaling. PI3K-pathways govern cell growth, proliferation, differentiation, motility 
and survival. PTEN deletions are reportedly detected in 20 to 60 percent of localized prostate 
cancer cases (Phin et al. 2013). PTEN loss is associated with ETS fusion positive cases, but is 
also detected in fusion negative cases, in which it seems to have the most negative effect to 
patient survival (Reid et al. 2010). Patients with no PTEN loss and no ETS rearrangements are 
reported to have better survival (Reid et al. 2010). PTEN activity can alternatively be 
diminished by aberrant expression of linked genes MAGI2 and PIK3CA, which have been 
associated with prostate cancer (Barbieri et al. 2012; Berger et al. 2011). PTEN is also shown 
to be downregulator of AR activity, and loss of PTEN is linked to development of androgen-
independent prostate cancer (Mulholland et al. 2006). 
 RB1 and TP53: RB1 and TP53 are both important cell cycle regulators and tumor 
suppressor genes commonly inactivated in multitude of cancer types. Loss of RB1 function is 
associated with onset of castrate-resistant prostate cancer and is detected in almost half of these 
cases (Grasso et al. 2012; Weischenfeldt et al. 2013). TP53 is commonly mutated or lost in both 
localized and progressed cases. Recent study with prostate cancer mouse models reports that 
RB1 loss facilitates metastatic processes initiated by loss of PTEN and that loss of TP53 causes 
resistance to antiandrogen therapy (Ku et al. 2017).  
 MYC: MYC is a proto-oncogene that drives cell cycle progression and cell survival 
processes. It is commonly amplified or overexpressed in prostate cancer (Gurel et al. 2008; 
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Taylor et al. 2010) and its overexpression is associated with more aggressive disease and cancer 
recurrence (Hawksworth et al. 2010; Rye et al. 2014). 
 NKX3-1: LOH in NKX3-1 is a common aberration in prostate cancer, typically 
resulting from deletion of chromosomal region 8p (Baca et al. 2013). NKX3-1 codes for a 
putative tumor suppressor transcription factor Nkx3.1, which in mouse studies is important to 
normal prostate epithelial differentiation and stem cell function (Shen and Abate-Shen 2010). 
 SPOP: SPOP is the gene with most frequently detected point mutations in prostate 
cancer and these mutations are mainly seen in ETS fusion negative cases (Barbieri et al. 2012). 
Protein coded by SPOP is a part of ubiquitin-protein ligase complex and is shown to stabilize 
the oncogene DEK by modifying its ubiquitylation state. This in turn was shown to increase 
invasive capabilities of prostate epithelial and LNCaP cells in vitro (Theurillat et al. 2014). 
Other possible prostate cancer-related target proteins for SPOP include ERG, Myc, and 
TRIM24 (Gan et al. 2015; Theurillat et al. 2014). 
 MicroRNAs and long noncoding RNAs in prostate cancer: Expression profiling 
studies of prostate cancer tissue samples show a large number of microRNAs aberrantly 
expressed in prostate cancer, with several of both up and downregulated microRNAs showing 
up in most of the material (Goto et al. 2015; Martens-Uzunova et al. 2012). A single microRNA 
typically regulates the expression of multiple genes and both probable tumor suppressive and 
oncogenic microRNAs have been identified (Fabris et al. 2016). Among the most interesting 
microRNAs are miR-21 and miR-141, whose overexpression has been associated with the 
development of castration resistant prostate cancer and metastatic disease, respectively (Ribas 
et al. 2009; Yaman Agaoglu et al. 2011). Interestingly, a recent study states that miR-141 has 
an inhibitory effect on metastasis and is actually downregulated in prostate cancer (Liu et al. 
2017). MicroRNA signatures are considered promising biomarkers, since they can be measured 
from different biological samples, they are relatively easy to detect and quantify, and they are 
stable molecules (Chen et al. 2008). 
 Data acquired by deep sequencing of prostate cancer transcriptome shows that long 
noncoding RNAs (lncRNAs) are abundantly expressed and several prostate cancer-specific 
lncRNAs have been identified (Prensner et al. 2011; Walsh et al. 2014; Ylipää et al. 2015). 
Together with deep sequencing data, functional studies suggest several mechanisms by which 
lncRNAs promote carcinogenesis. Prostate cancer gene expression marker 1 (PCGEM1), has 
shown to be overexpressed in over half of prostate tumors and reported to promote cell 
proliferation through modification of gene expression by enhancer-promoter looping (Petrovic 
et al. 2004). This is a feature commonly recognized in lncRNAs (Lai et al. 2013). Metastasis-
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associated lung adenocarcinoma transcript 1 (MALAT1) is overexpressed in prostate cancer and 
is associated with disease severity in other cancer types (Ji et al. 2003; Lin et al. 2007). MALAT1 
has been shown to regulate expression of several genes through modulation of alternative 
splicing (Bernard et al. 2010). Other cancer promoting mechanisms include antisense gene 
silencing and repressing of DNA repair mechanisms (Walsh et al. 2014). Prostate cancer 
antigen 3 (PCA3) is a lncRNA highly specific to prostate cancer, though not much of its 
function is known, and a PCA3 test for prostate cancer diagnosis is in clinical use (Bussemakers 
et al. 1999; Groskopf et al. 2006). MALAT1 has also been proposed as a prostate cancer 
biomarker that could be measured from blood plasma (Ren et al. 2013). 
 DNA methylation in prostate cancer: As with other cancers, CpG DNA methylation 
is highly deregulated in prostate cancer (Valdes-Mora and Clark 2015). In broad view, genomic 
DNA is hypomethylated, which is thought to lead to genome instability and activation of 
oncogenes (Brothman et al. 2005; Cho et al. 2009; Valdes-Mora and Clark 2015). Another 
characteristic is hypermethylation of certain promoter sequences. Over 50 genes, which are 
involved in cellular pathways critical for cancer development and progression such as cell cycle 
control, hormone response, DNA repair, tumor invasion and apoptosis, have been identified as 
commonly hypermethylated in prostate cancer (Jeronimo et al. 2011). 
2.2  Prostate cancer biomarkers 
Biochemical biomarkers are indicators of biological and pathological processes that can be 
measured with relative objectivity. Prostate cancer biomarkers are most commonly detected 
from patients’ blood, urine or tissue biopsy samples and can be utilized in diagnosis, estimating 
prognosis, predicting response to treatments, and detecting recurrence after curative treatment 
(Jakobsen et al. 2016). Due to heterogenous nature of prostate cancer, current biomarkers suffer 
from low diagnostic specificity and are not good enough in distinguishing indolent tumors from 
aggressive ones in the early stages of the disease (Jakobsen et al. 2016). Combinations of 
different urine or blood based biomarkers, such as TMPRSS2:ERG, PCA3 and PSA, and 
quantification of multiple genes or proteins from biopsy tissue samples are emerging as more 
powerful predictors (Mohler et al. 2016; Tomlins et al. 2016). Safety, easiness of use, low cost, 
reproducibility and convenience to patient are also important considerations that effect adoption 
of biomarker based tests in to clinical use.  
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2.2.1  Biomarkers clinically available for prostate cancer diagnosis and 
prognosis 
PSA: PSA, or human kallikrein 3, is a protein secreted by prostate epithelial cells into seminal 
fluid (Lilja H 1985). PSA is detectable in blood samples and its levels are elevated in prostate 
cancer as well as other conditions such as benign prostatic hyperplasia (Savblom et al. 2005). 
Although utilized earlier in monitoring treatment response and cancer recurrence, it was 
adopted in widespread diagnostic use in early 1990s and was approved by Food and Drug 
Administration (FDA) in 1994, which resulted in considerable increase in detection of early-
stage disease through increased number of prostate biopsies (Potosky et al. 2001). As stated 
earlier, part of the decrease in prostate cancer mortality can be attributed to widespread PSA 
testing (Kvale et al. 2007; Schroder et al. 2014). Its non-specificity, and in particular, the 
inability to distinguish docile cancer cases from aggressive ones, has led to over-treatment 
causing personal harm and increase in health-care expenses, which is in part why new 
biomarkers are actively sought (Schroder et al. 2014). PSA is well established and still the first 
line biomarker for prostate cancer detection. Due to its association with tumor volume and 
Gleason grade, and recent findings linking early age PSA levels to later development of 
metastatic disease, PSA will most likely continue to be utilized along with other markers in 
risk-stratification (Pinsky et al. 2007; Vickers et al. 2013). 
 Several improvements upon standard PSA testing have been proposed with some 
success. PSA velocity, which stands for increase rate of patient’s PSA levels between 
measurements, has been shown to be more accurate than single PSA measurement in predicting 
aggressive cancer cases, but the studies are controversial (Orsted et al. 2013; Vickers et al. 
2011). Prostate health index (PHI) is calculated by formula: ([-2]proPSA/free PSA) × √PSA, 
taking into account inactive precursor PSA ([-2]proPSA), activated free PSA and total PSA. 
There is considerable evidence that PHI improves predictive value upon standard PSA testing 
and could reduce unnecessary biopsies (Catalona et al. 2011; Jansen et al. 2010). PHI has been 
FDA approved since 2012. PSA density, where PSA levels are compared to the prostate 
volume, is reasoned to better distinguish between benign prostate hyperplasia and prostate 
cancer. Although earlier studies on the performance of PSA density are somewhat controversial 
and the sizing of prostate poses a challenge, a recent study has shown a significant increase in 
specificity when compared to use of free and total PSA (Cookson et al. 1995; Verma et al. 
2014). Another prostate-specific protein, human kallikrein 2 (hK2) is a serine protease that 
converts inactive pro-PSA to active PSA (Kumar et al. 1997). Its increased expression is more 
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specific to malignant conditions of the prostate and to high-grade disease than that of PSA’s 
(Darson et al. 1997). A panel combining total PSA, free PSA, intact PSA and hK2 has shown 
promising results in specificity to high-grade cancers and could possibly reduce unnecessary 
biopsies and over-treatment of low-risk tumors (Benchikh et al. 2010; Vickers et al. 2008). 
PCA3: PCA3 is a non-coding mRNA specific to prostate. It is overexpressed in 
prostate cancer cells and can be detected from urine samples after DRE (Hessels and Schalken 
2009). An FDA approved PCA3 assay is available for use in deciding on repeat biopsies after 
previous negative biopsies (Groskopf et al. 2006). PCA3 has limited value in detecting 
aggressive cancer cases, but it has shown to be an accurate predictor of indolent prostate cancer, 
and its use in selecting patients for active surveillance could be beneficial (Auprich et al. 2011). 
TMPRSS2-ERG fusion: As stated previously, TMPRSS2-ERG fusion is present in 
approximately half of prostate cancer cases and is associated with cancer-specific death and 
metastatic spread, although contradictory results have also been published (Tomlins et al. 
2009). TMPRSS2-ERG mRNA transcript can be detected from urine after DRE, and its use as 
a biomarker has been shown to increase specificity and prognostic capability of PSA based 
methods and PCA3 measurements (Leyten et al. 2014) 
ConfirmMDx: ConfirmMDx is a test based on the data from a next-generation 
sequencing study reporting prognostic value of epigenetic alterations in prostate cancer (Gu et 
al. 2015). It analyses methylation status of three genes: GSTP1, RASSF1, and APC, from 
negative biopsy tissue samples, and has been shown to have an 88% negative prediction value 
on repeat prostate biopsies in clinical setting (Partin et al. 2014). It has also been shown to 
improve the detection of high-grade cancer cases from negative biopsies, when combined with 
traditional risk stratification involving PSA levels and DRE (Van Neste et al. 2016). 
 Gene panels: Oncotype DX is a gene test that measures expression levels of 12 
prostate cancer-related and 5 housekeeping genes from needle biopsy samples with quantitative 
RT-PCR. Genes were selected from multiple prostate cancer-related pathways, based on results 
from prostatectomy and biopsy studies, with focus on genes associated with clinical recurrence, 
prostate cancer death, and adverse pathology at prostatectomy (Klein et al. 2014). Two 
independent studies have shown that the gene panel is a strong predictor of high-grade cancer 
and recurrence after radical prostatectomy (Cullen et al. 2015; Klein et al. 2014). 
 Prolaris is another gene panel used for prostate cancer risk stratification that utilizes 
quantitative RT-PCR measurements of 31 cell cycle-related genes and 15 housekeeping 
controls from needle biopsy samples. The test has been shown to independently predict prostate 
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cancer-specific mortality, biochemical recurrence after treatment, and metastasis (Cooperberg 
et al. 2013; Cuzick et al. 2015). 
Circulating tumor cells: Shedding of cells into the circulation is considered to be a 
property of the tumor that is associated with characteristics, other than the extent of cancer, 
conferring poor prognosis (Danila et al. 2011). Circulating tumor cells (CTC) can be counted 
with FDA approved Veridex CellSearch assay and detected high cell count is a reliable 
prognostic factor for poor survival time (Scher et al. 2009). The decrease in CTC count in 
response to first line chemotherapy of mCRPC is also strongly associated with longer survival 
time, and can be used to monitor treatment efficacy with greater predictive value than PSA 
decrease (Danila et al. 2011; Scher et al. 2009). Use of CTC in clinical practice is hindered by 
poor detection rate of current methods, which is probably the cause of substantial variation in 
survival times of patients with small CTC count (Danila et al. 2014). 
 In addition to enumeration, isolated CTCs can be molecularly profiled to gain insight 
of characteristics of the tumor of origin (Holcomb et al. 2009). CTC heterogeneity makes this 
approach less straightforward and it is still in experimental stages. A study showing that AR 
splice variant 7 mRNA (AR-V7) could be detected in CTCs, found that CRPC patients positive 
with the marker had worse treatment response to abiraterone and enzalutamide and had worse 
progression-free survival (Antonarakis et al. 2014). AR-V7 lacks the ligand-binding domain 
targeted by abiraterone and enzalutamide, but remains constitutively active. A study subjecting 
CTCs acquired from patients with metastatic prostate cancer to pathologic review, found that 
detection of CTCs with very small nucleus was associated with visceral metastases (Chen et al. 
2015). It was also noted that CTCs with very small nucleus were identified before the detection 
of visceral metastatic lesions, suggesting prognostic role for this type of approach. 
2.2.2  Promising biomarker research 
MicroRNAs: As stated earlier, widespread deregulation of microRNAs in prostate cancer has 
been reported compared to normal prostate tissues and altered microRNA 
expression profiles have been associated with prostate cancer properties, such as 
aggressiveness, metastasis, and recurrence (Martens-Uzunova et al. 2012; Tong et al. 2009). 
They are ideal as biomarkers as they can be measured from urine, blood, or tissue samples and 
they are stable molecules relatively easy to detect and quantify (Chen et al. 2008).  
Expression profiles of miR-221 have been shown to correlate with metastasis 
formation, recurrence risk after radical prostatectomy, tumor progression, and Gleason score 
(Kneitz et al. 2014; Spahn et al. 2010; Yaman Agaoglu et al. 2011). Prostate cancer cell line 
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studies indicate miR-221 as a tumor suppressor regulating cell growth, apoptosis, and 
invasiveness (Kneitz et al. 2014). A combination of expression of four microRNAs: miR-96-
5p, miR-183-5p, miR-145-5p, and miR221-5p, measured from tissue samples has been shown 
to outperform PSA in predicting diagnosis and to significantly predict tumor aggressiveness, 
metastasis, and overall survival of patients (Larne et al. 2013). The miR-21 is a known onco-
miR deregulated in several types of cancer and upregulation of miR-21 plasma levels is 
associated to development of castration-resistant prostate cancer (Selcuklu et al. 2009; Shen et 
al. 2012). It is regulated by AR and it has been shown to promote both hormone-dependent and 
hormone-independent prostate cancer growth (Ribas et al. 2009). Expression levels of miR-21 
have also been shown to predict treatment response to docetaxel-based chemotherapy (Zhang 
et al. 2011). Diagnostic and prognostic use of microRNAs in prostate cancer is founded in 
increasing experimental evidence, and consensus is forming on the microRNAs with most 
potential. As with all emerging biomarkers, differences in study design, sample collection, and 
in the techniques used in analysis should be minimized with development of proper guidelines 
(Fabris et al. 2016). 
 Nucleic acids in peripheral blood: Measuring of free circulating nucleic acid levels 
from peripheral blood, or mRNA levels in whole blood samples, can be used to characterize 
prostate cancer tumors. Interestingly, increase in total cell-free DNA in peripheral blood has 
been shown to associate with PSA-recurrence after radical prostatectomy (Bastian et al. 2007). 
A six-gene panel, measured with quantitative RT-PCR from peripheral blood of patients with 
CRPC, was shown to be able to group patients to low-risk group with a median survival of more 
than 34.9 months, and to high-risk group with median survival of 7.8 months (Ross et al. 2012). 
Another study utilized microarray analysis of over 47 000 transcripts from whole blood to 
categorize patients in to four prognostic groups based on expression profiles, with one of the 
groups significantly associated with CRPC and poor survival (Olmos et al. 2012).  A nine-gene 
panel was then pinpointed, which could reliably categorize patients into these groups.  
In an attempt to complement CTC count in prognosis of CRPC, a five-gene panel was 
created based on high expression in CRPC cases and prostate-specificity (Danila et al. 2014). 
Detection of two or more of these genes from whole blood samples could predict overall 
survival with similar accuracy to CTC count, and cases with poor survival despite a favorable 
CTC count were also identified. Another study searching surrogates for CTC count utilized 
peripheral blood mononuclear cell (PBMC) fraction. KLK3, PCA3, and TMPRSS2-ERG 
mRNAs were detected in 89%, 53%, and 37% of CRPC patients’ PBMC fraction, respectively, 
while healthy controls were negative for all markers (Dijkstra et al. 2014). Expression levels of 
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all the markers were found to be reduced in response to docetaxel treatment, suggesting this 
approach as candidate for treatment monitoring. A recent study has shown that AR-V7 can be 
directly quantified from peripheral whole blood samples to predict the progression-free survival 
of CRPC patients receiving abiraterone or enzalutamide treatment (Seitz et al. 2017). 
Copy-number aberrations: As stated earlier, CNAs are important and common 
mechanisms in prostate carcinogenesis, and overall CNA burden and specific CNAs could have 
prognostic potential. A study analyzing CNA burden as the percentage of the tumor genome 
affected by CNA found that it was significantly associated with biochemical recurrence and 
metastasis after radical prostatectomy (Hieronymus et al. 2014). The study also states that CNA 
burden can be measured in needle biopsy samples using low-input whole-genome sequencing, 
which would make it a more accessible prognostic option. Another study utilizing whole 
genome analysis pinpointed deletion of 8p23 as associated with advanced stage, and gain at 
11q13.1 predicting recurrence independently of cancer stage and grade (Paris et al.2004). In a 
more elaborate approach, unsupervised hierarchical clustering of tumors based on CNA data 
produced tumor subgroups with differing risk of relapse after radical prostatectomy. The 
difference in risk could not be explained by differential expression of individual genes (Taylor 
et al. 2010). These studies display the prognostic potential of CNA analysis, but additional 
validation and standardization of methods are needed before it can be utilized in clinical 
settings. 
 Exosomal biomarkers: Prostasomes are microvesicles produced by prostate acinar 
cells, normally released into seminal fluid. They have been found to be present in peripheral 
circulation of men with prostate cancer and their amount has been shown to correlate with 
Gleason score (Tavoosidana et al. 2011). Exosomal vesicles are stable and their RNA content 
is protected from exogenous RNAses. Vesicles’ molecular composition is considered to reflect 
composition of their cellular origin (Zijlstra and Stoorvogel 2016). These properties make them 
attractive for extraction of prostate cancer-specific markers and for example TMPRSS2:ERG 
and PCA3 RNAs have been detected from exosomal fractions from the urine of prostate cancer 
patients (Nilsson et al. 2009). MicroRNAs with biomarker potential can also be harvested from 
microvesicles and exosomes. This was utilized in study that compared microRNA content in 
serum-derived vesicles between recurrent and non-recurrent cancer cases following radical 
prostatectomy and found miR-141 and miR-375 to be associated with metastatic prostate cancer 
(Bryant et al. 2012). 
 20 
 
2.2.3  Short and long-term future of biomarkers 
The most established new urine and blood based biomarkers are close to have accumulated 
enough data to replace or to complement PSA testing as a standard method to decide whether 
to proceed to prostate biopsy. Thorough comparison of the different approaches is still needed 
to ensure that the new guidelines best utilize the capabilities of new biomarkers to reduce 
prostate cancer mortality and adverse effects of overtreatment. Tissue based tools, such as gene 
panels, could possibly be utilized more extensively to verify negative biopsies, and to assign 
patients with higher risk for recurrence after curative treatment to closer follow-up. 
 Promising research on gene panels and microRNAs suggest that they might prove 
important predictors and monitors for treatment efficacy. This could help to decide the most 
effective treatment modalities for both localized cancer and for mCRPC. Better treatment 
targeting will reduce side effects caused to patients and limit health care expenses. Possibly the 
highest hopes are set on microRNAs for their versatility, and because their expression levels 
reflect multiple prostate cancer-related pathways. 
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3  AIMS OF THE THESIS 
The goal of this Master’s thesis study was to assess the possible role of OXGR1 in prostate 
cancer. RNA sequencing data of clinical prostate cancer samples show significant 
overexpression of OXGR1 in small subset of samples. There are yet no studies proposing 
OXGR1 as a potential oncogene, but preliminary data of this group suggests that OXGR1 
overexpression could confer growth advantage to prostate cancer cells. The aims of this study 
were: 
1) To verify the overexpression in prostate cancer cells with stable and transient 
OXGR1 transfections at RNA and protein level. 
2) To corroborate the results of preliminary experiments showing possible growth 
advantage in OXGR1 overexpressing cells. 
3) To investigate possible mechanisms by which OXGR1 expression and protein 
coded by it, OXGR1, could confer growth advantage. This is performed by 
introducing OXGR1 expressing cells to growth media containing different 
concentrations of key substrates. 
 
  
 22 
 
4  MATERIALS AND METHODS 
4.1  Cell culture methods 
The study was carried out using two prostate cancer cell lines: PC-3 and LNCaP, which were 
obtained from American Type Culture Collection (ATCC).  Stable OXGR1 expressing PC-3 
and LNCaP cell lines were created previously by transfecting cells with pcDNA3.1 vectors 
(Invitrogen) containing OXGR1 and neomycin resistance gene under constituve promoter.  
Three OXGR1 transfected PC-3 cultures (PC-3 OXGR1_4, PC-3 OXGR1_8 and PC-3 
OXGR1_10) were chosen for the study based on previous results along with two cultures 
transfected with empty vectors (PC-3 pcDNA_1 and PC-3 pcDNA_3). Likewise, three OXGR1 
transfected LNCaP cultures (LNCaP OXGR1_2, LNCaP OXGR1_6 and LNCaP OXGR1_13 
were chosen for the study along with two cultures transfected with empty vectors (LNCaP 
pcdna_2 and LNCaP pcdna_4). 
PC-3 and LNCaP cells were cultured according to ATCC guidelines in Ham’s F12 
medium with 10% fetal bovine serum and in RPMI 1640 medium with 10% fetal bovine serum 
(Gibco, Life Technologies) respectively. Vector transfected lines were kept under constant 
selection pressure with 0.2 mg/ml Geneticin® (Thermo Fisher Scientific). 
4.2  Transient transfection 
A transient transfection was performed to PC-3 cells with OXGR1 cDNA in pEZ-MO2 vector 
(GeneCopoeia). pcDNA3.1 vectors were transfected as controls. Transfection was carried out 
using jetPei (Polyplus Transfection) according to manufacturer’s instructions with complex 
formation incubation time at 15 minutes.  
4.3  RT-qPCR 
Total RNA was extracted from pelleted cells harvested at ~80% confluence using TRI 
Reagent® (Sigma) following manufacturer’s guidelines. RNA concentrations were measured 
using Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific). Reverse transcription of 
RNA to cDNA was performed with Maxima reverse transcriptase with random hexamer 
primers (Thermo Fisher Scientific).  
OXGR1 RNA levels were quantified using standard curve derived from total RNA 
pooled from prostate cancer cell lines PC-3, 22Rv1 and LNCaP. OXGR1 levels were further 
normalized to housekeeping gene TATA-binding protein (TBP). Primer sequences for OXGR1 
were GCTGAACCTGGCCTGCACAGA forward and TGATCCACACCACAGCACAGGC 
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reverse, and for TBP GGGGAGCTGTGATGTGAAGT forward and 
GAGCCATTACGTCGTCTTCC reverse. Quantitative PCRs were performed with Maxima 
SYBR Green/ROX qPCR Master Mix (Fermentas) following manufacturer’s guidelines with 
optimized annealing temperature for both primer pairs. Equipment used was CFX96 q-RT-PCR 
detection system (Bio-Rad). Proper amplification was ensured by agarose gel electrophoresis 
of PCR products. Data analysis was performed with Excel software. 
4.4  Cell lysates, SDS-PAGE, and western blot 
Protein content was extracted from ~80% confluent cells using triton lysis buffer (0.5% Triton-
X 100, 300 mM NaCl in 50 mM Tris-HCL pH 7.4) supplemented to contain 1x Complete 
protease inhibitor cocktail (Roche), 1 mM dithiothreitol (DTT) and 1 mM 
phenylmethylsulfonyl fluoride (PMSF), and sonication with Bioruptor (Diagenode). Protein 
concentration was measured using DC Protein Assay (BioRad) and EnVision® 2104 multilabel 
reader. Bovine serum albumin (BSA) dilution series was used as standard. 
30 - 50 µg of protein lysate (same amount of protein in each sample of a single gel) 
was combined with Red Loading Buffer and DTT (New England Biolabs), and loaded to 10% 
SDS-PAGE gel. Kaleidoscope™ Prestained SDS-PAGE Standard (Bio-Rad) was also loaded 
into each gel. Gel was run on Bio-Rad equipment first ~30 min. at 50 V, then ~120 min. at 
120V. Proteins in the gel were then transferred to Immobilon P membranes using The Mini 
Trans-Blot® cell (Bio-Rad) according to manufacturer guidelines. The proper transfer time was 
optimized to ~45 min. at 50 V. 
 Unspecific binding was blocked in 3% BSA in phosphate-buffered saline (PBS) for 
1h RT, and washes were performed in PBS with 0.1% Tween-20. Membranes were probed with 
primary monoclonal anti-OXGR1 [EPR6305(2)] rabbit antibody (Abcam) for 1 h RT at 1:500 
dilution and with secondary polyclonal horseradish peroxidase (HRP)-conjugated swine anti-
rabbit antibody (Dako) for 30 min RT at 1:5000 dilution. Monoclonal pan-actin Ab-5 mouse 
antibody (Thermo Fisher Scientific) was used at 1:1000 dilution along with polyclonal HRP-
conjugated rabbit anti-mouse antibody (Dako) at 1:5000 dilution to verify even total protein 
content. Western Blotting Luminol Reagent SC-2018 (Santa Cruz) was then applied to 
membranes. X-ray films were exposed to membranes for 5 seconds to 10 minutes depending 
on the antibody and were developed using CP1000 table top film processor (Agfa). 
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4.5  Immunofluorescence staining 
For immunofluorescence staining, cells were seeded on coverslips to achieve ~80% confluence 
over 3 days. The day following the seeding, transient OXGR1 transfection was performed on 
part of the samples (see before). Third day from seeding, coverslips were rinsed with PBS and 
fixed with 4% paraformaldehyde 30 min RT. For antibody probing, cells were permeabilized 
with 0.5% NP-40 in PBS for 5 min RT. Unspecific binding was blocked in 3% BSA in PBS for 
10 min RT. Antibodies used were primary monoclonal anti-OXGR1 [EPR6305(2)] rabbit 
antibody (Abcam) for 1 h RT at 1:250 dilution and secondary fluorescent labeled Alexa Fluor 
594 goat-anti-rabbit antibody (Invitrogen) for 1 h RT at 1:100 dilution. Coverslips were 
mounted on microscope slides with Vectashield mounting media (Vectro Labs) containing 
DAPI. Cells were imaged with Zeiss Axio Imager M2 fluorescence microscope. 
4.6  Cell proliferation experiment 
For proliferation assay, the cells were seeded on 24-well plates as four replicates. Number of 
cells seeded was 15 000 cells / well for PC-3 cells and 30 000 cells / well for LNCaP cells. This 
was assigned day 0. At day 1 cells regular medium was adjusted to experimental conditions, 
and transient OXGR1 transfection was performed on part of the samples (see before) (Table 2).  
Table 2: Different media used for cells in proliferation assays. Regular medium defined above for 
different cell types. 
Experiment Medium 
Varying alpha-ketoglutarate 
Regular medium with added alpha-ketoglutarate to final 
concentrations of 0 µM, 25 µM, 75 µM and 1000 µM. 
Varying glucose / glutamine 
DMEM, low glucose (Gibco) adjusted to different conditions  
Normal: 2.5 g/l glucose and 2 mM L-glutamine 
Low glucose: 1 g/l glucose and 2 mM L-glutamine 
High glucose: 4.5 g/l glucose and 2 mM L-glutamine 
Low glutamine: 2.5 g/l glucose and 0 mM L-glutamine 
High glutamine: 2.5 g/l glucose and 4 mM L-glutamine 
Transient OXGR1 transfection Regular medium 
 Cells were imaged at indicated days with Olympus IX71 microscope, OASIS 
automation control system and Surveyor imaging software (Objective imaging Ltd.). Cell 
surface area was measured with an in-house macro for ImageJ software.  
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4.7  Small interfering RNA knockdown of OXGR-1 
OXGR-1 expression knockdown in stably expressing LNCaP cells was performed with two 
targeting sequences with Silencer Select Pre-designed siRNA (Ambion). 150 000 cells were 
seeded on 6 well plates and transfection mixture of 500 µl Optimem (Gibco), 0.9 µl of 20 µM 
stock of two siRNA molecules and 9 µl of INTERFERin® (Polyplus Transfection) was added 
to cells after 10 minutes of complex formation at RT. A non-targeting siRNA was used as a 
control. Cells were harvested at 72 h for protein and RNA extraction. 
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5  RESULTS 
5.1  OXGR1 expression quantification by RT-qPCR 
pcDNA3.1 vectors (Invitrogen) were used to constitutively overexpress OXGR1 in prostate 
cancer cell lines PC-3 and LNCaP. Overexpression at mRNA level was confirmed by using 
RT-qPCR. Expression levels of OXGR1 in different transfection lines and controls are shown 
in Figure 4. Expression in cell lines transfected with empty vector and in non-transfected  
 
Table 3: Relative OXGR1 expression levels of 
non-transfected cell lines 
controls is virtually non-existent, while cell 
lines with stable OXGR1 transfection show 
hundred- to thousand-fold increase in 
expression at mRNA level. PC-3 
OXGR1_10 shows over five folds higher 
expression than other transfected PC-3 clones, and LNCaP OXGR1_2 shows almost two folds 
higher expression than other transfected LNCaP clones. Minor expression was also measured 
Cell line 
Relative OXGR1 
expression 
Standard 
deviation 
PC-3 0.78 0.40 
PC-3 pcDNA_1 2.20 1.27 
PC-3 pcDNA_3 0.38 0.16 
LNCaP 1.13 0.89 
LNCaP pcDNA_2 0.52 0.11 
LNCaP pcDNA_4 0.86 0.66 
Figure 5: Expression of OXGR1 mRNA in LNCaP 
cells with stable OXGR1 overexpression knocked 
down with siRNA and non-targeting control. LNCaP 
pcDNA_2 as non-transfected control. Error bars 
represent standard deviations of RT-qPCR 
replicates. 
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Figure 4: A) Expression of OXGR1 mRNA in PC-3 cells with stable OXGR1 transfection, with empty 
expression vector, and non-transfected control. B) Expression of OXGR1 mRNA in LNCaP cells with 
stable OXGR1 transfection, with empty expression vector, and non-transfected control. Error bars 
represent standard deviations of RT-qPCR replicates.  
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in non-transfected cell lines, both PC-3 and LNCaP (table 3). siRNA targeting OXGR1 mRNA 
was used to knockdown OXGR1 expression at mRNA level. The knockdown effect was 
measured with RT-qPCR (Figure 5). siRNA transfection decreased OXGR1 expression 
significantly: approximately 9 folds reduction in LNCaP OXGR1_2 cell line was detected. 
Despite this, the expression stayed well above the expression of controls transfected with empty 
vector. Thus, a partial knockdown was achieved. 
5.2  Verification of OXGR1 overexpression by western blotting 
Western blot experiments were performed to cells to confirm OXGR1 expression at protein 
level and to semi-quantitate protein concentration in different cell lines. Protein content of cells 
were probed with anti-OXGR1 and monoclonal anti-pan-actin antibodies to verify OXGR1 
expression at protein level and to semi quantitatively compare expression levels between 
samples. PC-3 cells with stable OXGR1 transfection show a clear but weak band when probed 
with OXGR1 antibody (Figure 6). Based on the molecular marker the band contains protein 
with molecular weight above 50 kilodaltons, while the predicted band size for OXGR1 is 
approximately 38 kilodaltons. Pan-actin probing shows relatively even protein content between 
samples. There is no difference in OXGR1 antibody band intensity between cells transfected 
with OXGR1 and cells transfected with empty vector. The results are similar when regular PC-
Figure 6: Western blot showing protein from 
regular and transfected PC-3 cells, probed with 
OXGR1 and pan-actin antibodies. Arrows mark 45.7 
kilodalton band on molecular marker. Arrowheads 
mark OXGR1 bands. 
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Figure 7: Western blot showing protein from 
regular and transiently transfected PC-3 cells, 
probed with OXGR1 and pan-actin 
antibodies. Arrows mark 45.7 kilodalton band 
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3 cells are compared to cells with transient OXGR1 transfection (Figure 7). Here is also shown 
a probing with only the secondary antibody to verify that OXGR1 band is result from primary 
antibody binding. 
 LNCaP cells with stable OXGR1 transfection show higher intensity bands when 
probed with OXGR1 antibody than regular LNCaP cells and cells transfected with empty vector 
(Figure 8). Here, the band seems to have even a higher molecular weight than that seen with 
PC-3 cells, and two bands with minor difference in molecular weight can be seen. LNCaP cells 
with stable OXGR1 transfection treated with anti-OXGR1 siRNA have slightly weaker staining 
than those treated with non-targeting siRNA, while the pan-actin probing shows even signal 
(Figure 9). With all LNCaP OXGR1 antibody probings, formation of double bands can be 
detected. 
5.3  OXGR1 protein expression and localization analysis by 
immunocytochemistry 
To further study the expression and cellular localization of OXGR1, PC-3 cells were analyzed 
by immunocytochemistry. Approximately 30% of the transiently transfected PC-3 cells show 
increased OXGR1 expression, but similar effect can also be seen on the empty vector control 
sample (Figure 10). In PC-3 cells with stable OXGR1 transfections, the cell to cell differences 
in OXGR1 expression seem to be lower than those with transient transfections (Figure 11), 
 
 
Figure 8: Western blot showing protein from regular 
and transfected LNCaP cells along with one transfected 
PC-3 cell line, probed with OXGR1 and pan-actin 
antibodies. Arrows mark 45.7 kilodalton band on 
molecular marker. Arrowheads mark OXGR1 bands or 
places where the band would be. 
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Figure 9: Western blot showing protein from 
transfected LNCaP cells with siRNA treatment, 
probed with OXGR1 and pan-actin antibodies. 
Arrows mark 45.7 kilodalton band on molecular 
marker. Arrowheads mark OXGR1 bands or places 
where the band would be. 
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Figure 10: A) Immunofluorescent anti-OXGR1 staining of transiently transfected PC-3 cells 
(OXGR1I and OXGR1II) and cells transfected with empty vector (pcDNA3.1I and pcDNA3.1II). 
B) Same images merged with nuclear DAPI staining. 
A 
B 
A 
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although cells with higher expression levels can be seen. Cells with higher expression levels 
can also be seen in the control series. OXGR1 is seen to localize mainly to the cell membrane 
and to lesser extent to the cytoplasm. All images are acquired from representative cell areas. 
5.4  Cell proliferation experiment 
Cell proliferation experiments were carried out to study whether OXGR1 overexpression 
provides growth advantage to PC-3 and LNCaP cells. With transiently transfected PC-3 cells, 
a minor increase in growth area is seen compared to the cells transfected with empty vector 
(Figure 12). To study whether metabolic conditions affect the growth of OXGR1 expressing 
cells, cell proliferation experiments were carried out in media containing different 
Figure 11: A) Immunofluorescent anti-OXGR1 staining of PC-3 cells with stable OXGR1 
transfection (OXGR1_4, OXGR1_8 and OXGR1_10), cells transfected with empty vector 
(pcDNA_1 and pcDNA_3) and non-transfected PC-3 cells (PC-3) B) Same images merged with 
nuclear DAPI staining. 
A 
B 
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concentrations of key metabolites along with regular growth medium. Stable OXGR1 
transfection in PC-3 cells didn’t increase growth rate in comparison to cells transfected with 
empty vector in growth experiments with varying glucose and glutamine concentrations (Figure 
13). One exception to this is the experiment with low glutamine concentration, where cell line 
OXGR_8 has increased growth compared to all other cell lines (Figure 13). In an experiment 
with varying alpha-ketoglutarate (AKG) concentrations, no clear differences can be seen in 
growth rate between OXGR1 transfected and control PC-3 cell lines (Figure 14). In the same 
AKG experiment with LNCaP cell lines, minor increase in growth rate of lines with stable 
OXGR1 transfection is seen, when AKG is present in the medium (Figure 15). 
 
 
 
  
 
Figure 12: Relative growth of transiently transfected 
PC-3 cells (OXGR1) and cells transfected with empty 
vector (pcDNA3.1). Error bars represent standard 
deviations between replicates. 
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Figure 13: Relative growth of PC-3 cells with stable OXGR1 transfection (OXGR1_4, OXGR1_8 and 
OXGR1_10) in regular growth medium and media containing different concentrations of glucose and 
glutamine. A) Normal medium B) Ham’s F-12 C) Low glucose medium D) High glucose medium E) Low 
glutamine medium F) High glutamine medium. Media compositions are listed in table 1. Non-transfected PC-
3 cells (PC3) and cells transfected with empty vector (pcDNA1 and pcDNA3) serve as controls. Error bars 
represent standard deviations between replicates. 
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Figure 14: Relative growth of PC-3 cells with stable OXGR1 transfection (OXGR1_4, OXGR1_8 and 
OXGR1_10) in growth media containing different concentrations of AKG. A) 0 µM AKG medium B) 25 µM 
AKG medium C) 70 µM AKG medium D) 1000 µM AKG medium. Non-transfected PC-3 cells (PC3) and 
cells transfected with empty vector (pcDNA1 and pcDNA3) serve as controls. Error bars represent standard 
deviations between replicates. AKG = alpha-ketoglutarate. 
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Figure 15: Relative growth of LNCaP cells with stable OXGR1 transfection (OXGR1_2, OXGR1_6 and 
OXGR1_13) in growth media containing different concentrations of AKG. A) 0 µM AKG medium B) 25 µM 
AKG medium C) 70 µM AKG medium D) 1000 µM AKG medium. Non-transfected LNCaP cells (LNCaP) 
and cells transfected with empty vector (pcDNA2 and pcDNA4) serve as controls. Error bars represent 
standard deviations between replicates. AKG = alpha-ketoglutarate. 
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6  DISCUSSION 
OXGR1 codes for a G-protein coupled receptor OXGR1, which is expressed mainly in human 
kidney, placenta, lung, trachea, salivary glands, eosinophils, mast cells, and nasal mucosa 
(Kanaoka et al. 2013; Shirasaki et al. 2017; Wittenberger et al. 2002). The receptor is activated 
by its ligands AKG and cysteinyl leukotrienes, particularly Leukotriene E4 (LTE4) (He et al. 
2004; Kanaoka et al. 2013). Studies on the biological function of OXGR1 are yet limited, but 
some propositions have been made. It has been shown that AKG levels respond to acid-base 
stress in mouse kidney tubules and, in turn, cause secretion of bicarbonate through activation 
of OXGR1 to further buffer the urea (Tokonami et al. 2013). Effects mediated through LTE4 
seem to play a role in hypersensitivity immune reactions, causing vascular leakage particularly 
in epithelial smooth muscle cells (Kanaoka et al. 2013; Shirasaki et al. 2017). 
OXGR1 was chosen as the target gene of this study on the grounds of unpublished 
data of this group showing high overexpression of OXGR1 at RNA level in a small subset of 
clinical prostate cancer samples. There is no published data suggesting OXGR1 to be a cancer 
promoting factor. Preliminary cell proliferation experiments also showed increased growth rate 
of PC-3 cells with both stable and transient OXGR1 transfection. The purpose of this study was 
to verify the earlier results showing increased growth rate, verify the overexpression of OXGR1 
both at RNA and protein level, and localize OXGR1 expression. Additionally, it was studied 
whether varying concentrations of substrates relevant to the OXGR1 pathway have effect on 
the growth of OXGR1-overexpressing prostate cancer cells.  
 LNCaP and PC-3 cell lines were chosen for the studies because they are both well 
characterized prostate adenocarcinoma cell lines. PC-3 cells are more advanced prostatic cancer 
cells that are insensitive to androgens, while LNCaP cells are sensitive to androgens. 
6.1  Verification of OXGR1 overexpression and cellular localization 
of OXGR1 
RNA expression was measured with standard RT-qPCR methods, and the OXGR1 mRNA 
quantity was normalized to TBP mRNA. A major overexpression of OXGR1 is seen in all the 
transfected cell lines (Figure 4). This is expected as OXGR1 was overexpressed under 
cytomegalovirus (CMV) promoter, which typically induces a very strong expression. The RT-
qPCR experiments have been repeated, making it fairly certain that the expression vector is 
performing as expected and that overexpression has been achieved. Stable transfection is 
performed by integrating OXGR1 expressing pcDNA3.1 plasmids (Invitrogen) into cells’ 
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genomes, so the differences between the RNA expressions of transfected lines could be due to 
differences in number of integrated plasmids.  
Non-transfected cells and cells transfected with empty expression vector, both PC-3 
and LNCaP, show minor OXGR1 expression levels (table 2). This is expected, as Human 
Protein Atlas shows minor OXGR1 expression in RNA sequencing of the normal prostate tissue 
samples (Fagerberg et al. 2014). siRNA silencing of OXGR1 expression in LNCaP OXGR1_2 
was performed to verify that the band seen in western blot experiments (Figure 9) with OXGR1 
antibody is indeed OXGR1. In RT-qPCR measurements it is seen that anti OXGR1 siRNA 
greatly reduces the RNA levels of OXGR1, around 90% (Figure 5). Yet, the siRNA treated 
sample still has OXGR1 expression levels much higher than the controls not transfected with 
OXGR1. 
The verification of OXGR1 overexpression at protein level proved to be challenging. 
In western blot experiment, anti-OXGR1 antibody produces a band of similar intensity in PC-
3 cells with stable OXGR1 transfection and in non- and control transfected cells (Figure 6). 
Results are the same with transiently transfected PC-3 cells and non-transfected control (Figure 
7). With LNCaP cells, the bands produced with anti-OXGR1 antibody seem to be significantly 
more intense in the cells with stable OXGR1 transfections than in the non- and control 
transfected cells (Figure 8). There is only a very minor difference in anti-OXGR1 band intensity 
between anti-OXGR1 siRNA-treated LNCaP OXGR1_2 and non-targeting siRNA-treated 
LNCaP OXGR1_2 (Figure 9). This is somewhat unexpected, as 90% reduction in mRNA levels 
would be expected to translate to a detectable difference in protein level. It could therefore be 
considered an indication of non-specific antibody binding. 
The clear bands seen in western blot experiments when probed with anti-OXGR1 
antibody seem to have molecular weight of 45 kilodaltons or more (Figures 6-9), while the 
predicted size of OXGR1 based on amino acid composition is 38 kilodaltons. In addition, 
material from Abcam shows bands around 38 kilodaltons in size when various non-prostate 
tissue samples are probed with anti-OXGR1 antibody. In the western blot with stably 
transfected LNCaP cells two bands are seen, where the lighter one corresponds to the band seen 
in the western blot with stably transfected PC-3 cells, and the heavier one is not seen in PC-3 
cells (Figures 6 and 8). These bands could be the result of differing post translational 
modifications of OXGR1, taking place only in LNCaP cells. Because of the protein denaturing 
during SDS-PAGE, different protein folds should not result in different bands in western blot. 
Discrepancies in band size and the fact that substantial OXGR1 overexpression at 
mRNA level doesn’t seem to translate to high expression at protein level raise the question 
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whether the antibody is binding properly. The difference between predicted size and the band 
size in western blot experiments could be explained through post-translational modifications. 
For example, SUMOylation would cause a similar shift in band size. Regulation on the level of 
OXGR1 translation and degradation could keep the protein levels low despite the 
overexpression at RNA level. Formation of band due to non-specific binding of the secondary 
antibody was ruled out by probing PC-3 cells with secondary antibody only (Figure 7). It is still 
possible that the band seen in western blot experiments is due to non-specific binding of the 
anti-OXGR1 antibody, but this is unlikely since the experiments suggest a difference in protein 
expression level of the OXGR1 transfected LNCaP cells. 
 One way to verify the presence of OXGR1 and to possibly gain insight on why the 
protein concentration is low or non-existent despite high overexpression at mRNA level, would 
be determination of protein half-life by cycloheximide chase analysis. In it, a flagged OXGR1 
would be transfected to PC-3 cells, cycloheximide would be used to inhibit further protein 
synthesis, and protein degradation rate would be analyzed by western blots with anti-flag 
antibodies at chosen time points.  
The results of the anti-OXGR1 immunostaining seem to be in line with the western 
blot results. OXGR1 expression was detected in roughly 20 to 30 percent of PC-3 cells in the 
population regardless whether the cells had been transfected with OXGR1 or not (Figures 10 
and 11). All cells with stable OXGR1 transfection should be capable to express OXGR1, as the 
selection pressure produced with aminoglycoside antibiotic Geneticin® should eliminate cells 
with no expression vector. Since OXGR1 has a function in acid-base balance through regulation 
of bicarbonate secretion and inflammatory signaling through LTD4, expression of OXGR1 
could be individual cell’s response to these stresses (Kanaoka et al. 2013; Tokonami et al. 
2013). This could explain the expression in only part of the cell population at a given time. 
OXGR1 has shown to be a G protein–coupled receptor (Wittenberger et al. 2002), so its 
localization mainly to the cell membrane is to be expected. Earlier study confirms this finding 
and shows that OXGR1 is internalized when bound to a ligand (He et al. 2004). Put together, 
the data from western blot and immunostaining experiments suggests that PC-3 cells natively 
express OXGR1 at modest levels and that its overexpression is kept in check by translational, 
post-translational and degradation regulation.  Immunostaining of LNCaP cells could not be 
performed due to time constraints. 
 
 
 
 38 
 
6.2  OXGR1 effects to cell proliferation 
PC-3 cells with transient OXGR1 transfection showed a minor increase in growth rate compared 
to cells transfected with empty vector (Figure 12). Further growth rate experiments were 
performed with cells with stable OXGR1 transfections and non- and control-transfected PC-3 
cells. Experiments were carried out in media containing different concentrations of key 
metabolic agents: glucose, glutamine, and AKG, along with regular media. Glucose is included 
as it is an important metabolite in aerobic and anaerobic metabolism and because tumors often 
utilize increased glucose uptake and increased utilization of glucose in biosynthetic processes 
(Anastasiou 2017). Glucose levels used ranged from fasting blood sugar (1 g/l) to standard for 
cells with high energy demand (4.5 g/l). Glutamine is the main link between the anabolic and 
catabolic amino acid metabolism and energy metabolism. It is also linked to redox state 
regulation through glutaminolysis to glutathione, which is a potent antioxidant. This pathway 
is typically over activated in prostate cancer due to elevated MYC oncogene activity (Fleming 
et al. 1986; Gao et al. 2009). Glutamine is also converted to AKG through glutamate in 
mitochondria. The glutamine levels used in this study ranged from starvation level (0 mM) to 
standard for cells with high energy demand (4 mM). AKG was chosen mainly as it is ligand for 
the OXGR1 (He et al. 2004). It also is an important intermediate in energy metabolism and 
anabolic and catabolic reactions. AKG levels used were starvation (0 µM), regular plasma level 
(25 µM), level required to activate OXGR1 (75 µM) and excess level (1 mM) (He et al. 2004). 
While there is no direct experimental evidence, it can be hypothesized that OXGR1 activation 
through binding to AKG is involved in energy metabolism and detecting surrounding metabolic 
states. 
Varying glucose and glutamine levels don’t seem to have much impact to growth rate 
of PC-3 cells, independent of OXGR1 transfection status (Figure 13). Exception to this is the 
experiment with no glutamine in which the growth of all cell lines ceases. Most reliable data 
can be acquired from day 4 or 5 of the experiments, when the cells still have space to grow. 
Considering all experiments, non-transfected PC-3 cells seem to have the fastest growth rate, 
while OXGR1 transfected cells seem to have the slowest growth rate (Figure 13). This may be 
explained by the burden the transfection imposes to cells, in particular to the ones producing 
excessive amounts of OXGR1 mRNA. The experiment with varying AKG concentrations gave 
similar results, with no clear difference in growth between different cell lines (Figure 14). 
Because there is no difference in OXGR1 levels based on western blot, or even no OXGR1 
present if the band is due to non-specific binding of the antibody, the results are expected.  
 39 
 
Comparison is made difficult by high standard deviations between replicates. This is 
somewhat expected in this kind of experimental setup. Even seeding of the cells to the wells 
takes a lot of practice, and minor differences in the cell confluence in the beginning can lead to 
big deviations.  There were also problems with the autofocus function of the microscope 
equipment, which may have caused part of the deviation. Some of the deviation could be 
eliminated by better equipment, more repeats of the experiment, and increasing the number of 
replicas in a way that outliers could be disregarded. 
Growth rate experiment with varying AKG concentrations was repeated using LNCaP 
cell lines (Figure 15). In this experiment, there seems to be a modest increase in the growth rate 
of OXGR1 transfected cell lines compared to the non- and control-transfected cell lines when 
AKG is present in the medium. Comparison is again made difficult by high standard deviations 
between replicas. Since there is a possible overexpression of OXGR1 at protein level in LNCaP 
cells, the minor increase in OXGR1 expressing cells growth rate could indeed be caused by 
OXGR1. It is, however, also possible that the biological significance of OXGR1 
overexpression, if any, lies in other aspects of cancer promotion than growth, for example 
immune and apoptosis evasion or tissue invasion.   
6.3  Future directions 
The results of the experiments with LNCaP cell lines are promising and they should be the 
focus of further studies. There is still concern that OXGR1 expression at protein level is not 
reliably verified with the antibody used in western blot experiments. The validation of antibody 
can be achieved by a combination of following methods: performing the immunocytochemistry 
experiment with LNCaP cells, repeating western blot experiments with other OXGR1 
antibodies, examining cell lines or tissues of known OXGR1 expression level and finally by 
producing an OXGR1 knockout PC-3 cell line. Possible post-translational modifications of 
OXGR1 could be studied with different chromatography methods and mass spectrometry. 
If the overexpression of OXGR1 in LNCaP cell lines can be confirmed, its biological 
effects must be put under further scrutiny. Cell invasion and migration studies are a logical next 
step, since they are relatively simple and affordable to perform for example using commercially 
available invasion chambers. By considering what is already known about the biological 
function of OXGR1, it is possible to make educated guesses about its function in cancer. One 
of the known functions of OXGR1 is to cause secretion of bicarbonate in kidneys in response 
to environment becoming more acidic (Tokonami et al. 2013). This causes better buffering and 
neutralization of extracellular pH, which is somewhat counterintuitive when considering cancer 
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promotion. Acidic microenvironment is considered a hallmark of cancer and it can promote 
cancer through three major mechanisms: by destruction of adjacent normal cell populations, by 
acid-induced degradation of extracellular matrix, and by angiogenesis promotion (Gatenby and 
Gillies 2004). OXGR1 is also shown to be a receptor for LTE4 (Kanaoka et al. 2013), a cysteinyl 
leukotriene involved in pulmonary inflammation and vascular permeability (Maekawa et al. 
2008). It has also been shown that it is indeed OXGR1 that mediates the increased vascular 
permeability response to LTE4 (Kanaoka et al. 2013). Increased vascular permeability is a 
known cancer promoting factor that can facilitate metastasis and modulate immune response 
(Farnsworth 2014). One possible way to study this line of thought further is to overexpress 
OXGR1 in a mouse model that has increased likelihood of developing prostate cancer, and 
compare cancer incidence, immune response markers, and histopathology of the tumors. 
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7  CONCLUSIONS 
Main goals of the study were to confirm OXGR1 overexpression in transfected prostate cancer 
cell lines PC3 and LNCaP, to corroborate earlier experiments showing increased growth rate of 
cells transfected with OXGR1 and to study the effect of key substrates to growth of transfected 
cells. 
OXGR1 overexpression could not be confirmed in PC-3 cells. Western blot 
experiments showed a band of similar intensity in the OXGR1 transfected lines and in the 
control cell lines. Correspondingly the immunocytochemistry showed similar expression 
patterns in transfected and control cell lines. There remains some concern whether the antibody 
performed properly, since the band detected was ~10 kilodaltons larger than predicted. Growth 
rate experiment with transiently transfected PC-3 cells showed a minor increase in growth rate 
in transfected cells compared to control cells. This result could not be confirmed with stable 
OXGR1 expressing cell lines. Adjustment of concentration of glucose, glutamine and AKG in 
growth medium didn’t have an effect to growth rate of OXGR1 transfected PC-3 cells in 
comparison with control cells. 
Western blot experiments with OXGR1 transfected LNCaP cells showed a band of 
same molecular weight as in PC-3 cells that was missing from the control LNCaP cells. Growth 
rate experiments show a minor increase in growth rate of OXGR1 transfected LNCaP cells, in 
comparison to control LNCaP cells, when AKG is present in the growth medium. 
Since a clear difference is seen in intensity of western blot bands produced with 
OXGR1 antibody between transfected and control LNCaP cells, it is likely that the antibody is 
working properly and the difference to predicted band size is due to post-translational 
modifications to OXGR1. This result must be validated in future studies. This would mean that 
the PC-3 cells have basal expression of OXGR1 and that the excess mRNA is either not 
translated to protein, or the excess protein is rapidly degraded. As overexpression of OXGR1 
is achieved in LNCaP cells, the stable expressing cell lines can be used in further studies to 
elucidate the possible role of OXGR1 in prostate cancer promotion. 
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